These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 34964652)

  • 21. Optical Coherence Tomography Biomarkers Predicting Visual Acuity Change after Intravitreal Bevacizumab Injections for Macular Edema Secondary to Branch Retinal Vein Occlusion.
    Segal O; Yavnieli R; Mimouni M; Rabina G; Geffen N; Moisseiev E; Nemet AY
    Ophthalmologica; 2022; 245(1):19-24. PubMed ID: 34510041
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion.
    Jaissle GB; Szurman P; Feltgen N; Spitzer B; Pielen A; Rehak M; Spital G; Heimann H; Meyer CH;
    Graefes Arch Clin Exp Ophthalmol; 2011 Feb; 249(2):183-92. PubMed ID: 21337042
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The short-term efficacy of intravitreal ranibizumab, aflibercept and dexamethasone implant in the treatment of macular edema due to non-ischemic central retinal vein occlusion.
    Yucel OE; Birinci H; Sullu Y
    Int Ophthalmol; 2019 Apr; 39(4):891-901. PubMed ID: 29550932
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION.
    Lotfy A; Solaiman KAM; Abdelrahman A; Samir A
    Retina; 2018 Sep; 38(9):1795-1800. PubMed ID: 28767552
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bevacizumab versus bevacizumab and macular grid photocoagulation for macular edema in eyes with non-ischemic branch retinal vein occlusion: results from a prospective randomized study.
    Callizo J; Atili A; Striebe NA; Bemme S; Feltgen N; Hoerauf H; Bertelmann T
    Graefes Arch Clin Exp Ophthalmol; 2019 May; 257(5):913-920. PubMed ID: 30610424
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab.
    Spooner K; Fraser-Bell S; Hong T; Chang A
    Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of natural course, intravitreal triamcinolone, and intravitreal bevacizumab for treatment of macular edema secondary to branch retinal vein occlusion.
    Kwon SI; Kim YW; Bang YW; Lee JY; Park IW
    J Ocul Pharmacol Ther; 2013 Feb; 29(1):5-9. PubMed ID: 23237542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of intravitreal bevacizumab and dexamethasone implant for the treatment of macula oedema associated with branch retinal vein occlusion.
    Kim M; Lee DH; Byeon SH; Koh HJ; Kim SS; Lee SC
    Br J Ophthalmol; 2015 Sep; 99(9):1271-6. PubMed ID: 25777815
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A 12-month, multicenter, parallel group comparison of dexamethasone intravitreal implant versus ranibizumab in branch retinal vein occlusion.
    Bandello F; Augustin A; Tufail A; Leaback R
    Eur J Ophthalmol; 2018 Nov; 28(6):697-705. PubMed ID: 29631435
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of three different intravitreal treatment modalities of macular edema due to branch retinal vein occlusion.
    Kaldırım HE; Yazgan S
    Int Ophthalmol; 2018 Aug; 38(4):1549-1558. PubMed ID: 28646440
    [TBL] [Abstract][Full Text] [Related]  

  • 31. "Off-label" use of intravitreal bevacizumab in non-ischemic macular edema secondary to retinal vein obstructions.
    Dascalu AM; Popa-Cherecheanu A; Popa-Cherecheanu M; Nica A; Serban D
    Rom J Ophthalmol; 2016; 60(2):90-95. PubMed ID: 29450329
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low frequency ranibizumab versus dexamethasone implant for macular oedema secondary to branch retinal vein occlusion.
    Yuksel B; Karti O; Celik O; Kerci SG; Kusbeci T
    Clin Exp Optom; 2018 Jan; 101(1):116-122. PubMed ID: 28922697
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical, anatomical, and electrophysiological assessments of the central retina following intravitreal bevacizumab for macular edema secondary to retinal vein occlusion.
    Loukianou E; Brouzas D; Chatzistefanou K; Koutsandrea C
    Int Ophthalmol; 2016 Feb; 36(1):21-36. PubMed ID: 25820576
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up.
    Wu L; Arevalo JF; Roca JA; Maia M; Berrocal MH; Rodriguez FJ; Evans T; Costa RA; Cardillo J;
    Retina; 2008 Feb; 28(2):212-9. PubMed ID: 18301025
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-life clinical data for dexamethasone and ranibizumab in the treatment of branch or central retinal vein occlusion over a period of six months.
    Winterhalter S; Eckert A; Vom Brocke GA; Schneider A; Pohlmann D; Pilger D; Joussen AM; Rehak M; Grittner U
    Graefes Arch Clin Exp Ophthalmol; 2018 Feb; 256(2):267-279. PubMed ID: 29185099
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SD-OCT pattern of retinal venous occlusion with cystoid macular edema treated with Ozurdex®.
    Coscas G; Coscas F; Zucchiatti I; Glacet-Bernard A; Soubrane G; Souïed E
    Eur J Ophthalmol; 2011; 21(5):631-6. PubMed ID: 21500185
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The influence of anti-VEGF therapy on present day management of macular edema due to BRVO and CRVO: a longitudinal analysis on visual function, injection time interval and complications.
    Papadia M; Misteli M; Jeannin B; Herbort CP
    Int Ophthalmol; 2014 Dec; 34(6):1193-201. PubMed ID: 25245600
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL Report No. 1.
    Narayanan R; Panchal B; Das T; Chhablani J; Jalali S; Ali MH;
    Br J Ophthalmol; 2015 Jul; 99(7):954-9. PubMed ID: 25631483
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravitreal Dexamethasone Implant versus Intravitreal Ranibizumab for the Treatment of Macular Edema Secondary to Retinal Vein Occlusion in a Chinese Population.
    Gu X; Yu X; Song S; Dai H
    Ophthalmic Res; 2017; 58(1):8-14. PubMed ID: 28334720
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Short-term and long-term results after intravitreal bevacizumab therapy for macular oedema in branch retinal vein occlusion.
    Pidro A; Pidro A; Nadarevic-Vodencarevic A; Halilbasic M; Lepara O; Nisic F
    Rom J Ophthalmol; 2022; 66(1):22-26. PubMed ID: 35531462
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.